Gamma Secretase Modulators Show Promise in Alzheimer's Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
LA JOLLA, Calif., March 31 /PRNewswire/ -- Gamma secretase
(GSMs) have shown promise in Alzheimer's disease animal model efficacy
studies, according to research conducted by TorreyPines Therapeutics, Inc.
(Nasdaq: TPTX ).
Presented by Steven Wagner, Ph.D., the company's Chief Sci...
EnVivo to Share Results of its EVP-6124 Phase Ib/IIa Trial at The International Conference on Alzheimer's Disease
... with EVP-0334 as the lead molecule for cognition in Alzheimer's disease which is in Phase 1 studies, and several preclinical programs such as a Gamma secretase
Modulator (for Alzheimer's disease) and a PDE10 inhibitor program (for Schizophrenia). For more information about EnVivo, visit www.envivopharma...
EnVivo and Mitsubishi Tanabe Enter License Agreement on EVP-6124 in Japan, Korea, Taiwan and Other Asian Countries
...enetics program based on Histone Deacetylase inhibition (HDACi) for cognition in Alzheimer's disease, and several preclinical programs such as a Gamma secretase
Modulator and a PDE10 inhibitor. For more information about EnVivo, visit www.envivopharma.com .
About Mitsubishi Tanabe Pharma Corporation ...
Alzheimer's Drug May Someday Help Head Trauma Victims
...n found that amyloid peptide production after brain injury was reduced in mice that received an experimental agent called DAPT, one of the first gamma secretase
inhibitors developed and the basis for some Alzheimer's disease drugs now in clinical trials.
The researchers said that their findings, which are p...
New Class of Drugs May Fight Alzheimer's
...accumulation of amyloid beta."
Until now, anti-amyloid drugs have fallen into three broad classes: immunotherapies, anti-aggregation compounds, and secretase
modulators, Gandy said. "The new work suggests that there exist single drugs that possess both of the latter two activities, thereby supplying an anti...
TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments
...nted animal data on TorreyPines' proprietary gamma secretase
modulator (GSM) compounds at the Keystone Symp... provide a more selective mechanism than gamma secretase
inhibitors. TorreyPines is developing its GSM ...atment for xerostomia, the
potential for the gamma secretase
modulator compounds to treat Alzheimer's
Flavonoids May Help Treat Alzheimer's
...ew York City.
"Both Alzhemed and statins were effective in mice, yet failed in the clinic, so the flavonoid data join NSAIDs, vaccines, PBT2, IVIg, secretase
modulators, among others, in the queue of interventions that look promising in mice but remain to be thoroughly assessed in humans," Gandy said.
Ground-breaking new insight into the development of Alzheimer's disease
...l form of Alzheimer's disease (less common form). -secretase, which cuts proteins at a specific location C plays an important role here. Sometimes the secretase
cuts in the wrong place, which results in a by-product and thus the formation of plaques.
In the most common form of the disorder the same sort of pl...
Novel discovery by Einstein scientists could lead to much-needed kidney failure treatment
...tect the rats from developing kidney disease by injecting them with a gamma secretase
inhibitorone of a class of compounds known to shut off the Notch pathway. ...om the University of Michigan Medical Center. The experts noted that gamma secretase
inhibitors, like the one that protected the mice from kidney disease in thi...
Same process discovered to both form skeleton and protect it for life
In further tests, researchers found that two secretase
inhibitors, which shut down Notch signaling, also ...nyl]-S-phenylglycine t-butyl 10 ester), is a gamma secretase
inhibitor. Gamma secretase
snips off the Notch proteins tail (NICD) inside th...
Secretase in Medical Technology
Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
... II and anti-HGF in Phase I;
Two projects for Alzheimer's -- a beta secretase
inhibitor and a gamma secretase
A novel anti-inflammatory agent, anti-IL-23, in Phas...
Phase II Data on Lilly's Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimer's Disease
...ionally we are currently enrolling patients into the Phase III study
called IDENTITY, which examines treatment with LY450139, an investigational
inhibitor believed to slow the rate of formation of amyloid
beta, potentially slowing disease progression. These two neuroscience
pipeline candidates ...
Markers in Blood and Spinal Fluid, and a New Imaging Agent, Show Promise for Early Detection of Alzheimer's
...l Institute on
Aging, Dana Foundation, Anonymous Foundation, Charles and Joanne Knight
-- Harald Hampel. "Alteration of beta secretase
candidate biomarkers in subjects with mild cognitive impairment and
Alzheimer's disease." (Funders: Science Foundation Ireland, Fed...
EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
...ase inhibitor (HDACi) for Huntington's disease is
scheduled for clinical entry later in 2008. The company's other preclinical
programs include a Gamma secretase
Modulator and a PDE10 inhibitor. For
more information about EnVivo, please visit http://www.envivopharma.com .
Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease
...stCall/ -- Eli Lilly and Company
(NYSE: LLY ) has announced today the start of a Phase III clinical trial
studying LY450139, an investigational gamma secretase
inhibitor for the
treatment of mild to moderate Alzheimer's disease. LY450139 is being tested
to see if it can slow the progression associated with Al...
Secretase in Biological News
Alzheimer's disease drug treats traumatic brain injury, report GUMC researchers
...activating these pathways in part by using a gamma secretase
inhibitor - a class of Alzheimer's disease drugs c...cretase. Agents that inhibit the activity of gamma secretase
are now being studied as treatment for Alzheimer's...re either treated with DAPT, an experimental gamma secretase
inhibitor, or mice which were "BACE knock-outs" s...
Alzheimer's disease therapeutic prevents long-term damage from TBI in pre-clinical studies
That is because the agents, known as gamma secretase
inhibitors, are designed to prevent build-up of am...ain injury treatment. It worked. "By using a gamma secretase
inhibitor, we prevented much of secondary traumati...he experimental agent DAPT, one of the first gamma secretase
inhibitors developed and the model upon which some...
New therapeutic target identified for rheumatoid arthritis
...l for Special Surgery in New York City. He said that drugs, so-called gamma secretase
inhibitors that hit this new target, are actually in trials for the treatme...Dr. Ivashkiv. He says that other studies have shown that drugs called gamma secretase
inhibitors have been shown to interfere with the Notch pathway and thus cou...
Moss protein plays role in Alzheimer's disease
...ccumulates in amyloid plaques, associated with the disease. Another common site for mutations is found in presenilin (PS) proteins. The enzyme gamma secretase
contains PS and works to dispose of proteins stuck in the cellular membrane.
This enzyme with PS at its core mediates two cellular decisions. On...
A sweet solution for Alzheimer's disease?
...vaccine," the researcher said.
Another complication with previous attempts to treat Alzheimer's disease has been that some compounds--such as beta secretase
inhibitors--cannot enter the brain easily, St George-Hyslop explained. Scyllo-inositol, on the other hand, readily passes through the blood-brain barr...
Targeting a key enzyme with gene therapy reversed course of Alzheimer's disease in mouse models
... (APP) releasing the toxic beta amyloid fragments that clump together to form the sticky plaques. One of the enzymes doing the cleaving is called beta secretase
And although the production of beta amyloid occurs in all brains, healthy brains are able to clear away excess amounts. Brains of people ...
Secretase in Biological Technology
EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimer's Disease
... with EVP-0334 as the lead molecule for cognition in Alzheimer's disease which is in Phase I studies, and several preclinical programs such as a Gamma secretase
Modulator (for Alzheimer's disease) and a PDE10 inhibitor program (for schizophrenia). For more information about EnVivo, visit www.envivopharm...
EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimer's Disease Transgenic Mouse Model With Gamma-Secretase Modulator
...nt of AB. As EVP-0962 does not affect other gamma secretase
substrates required for normal function, such as N...nsically superior safety profile compared to gamma secretase
EVP-0962 selectively r..., and several preclinical programs such as a Gamma secretase
Modulator (for Alzheimer's disease) and a PDE10 in...
Progress toward an Alzheimer's drug that saves brain cells
...ariety of tissues. They have now been able to demonstrate that the complex assumes a different shape and function according to the tissue in which the secretase
is active. For their research on Alzheimer's disease, the researchers have used mouse models. They have found that deactivating the variant, Aph1B &ga...
Lilly Highlights Transformation Strategy for Wall Street, Reviews Robust Pipeline and Sets 2009 Financial Guidance
...e letter and is currently awaiting the
FDA's final review.
-- Gamma secretase
Inhibitor - In March 2008, the company began its first
pivotal trial in Alzheimer's disease for the gamma secretase
small molecule designed to reduce the levels of the amyloid be...
TorreyPines Therapeutics Sells Alzheimer's Disease Genetics Program to Eisai
... discovery programs
focused on Alzheimer's disease, the other being a gamma secretase
(GSM) program. Recently, a lead compound from the GSM program has... no guarantee that TorreyPines will be able to find a
partner for the gamma secretase
modulator program. These and other risks
which may cause results to differ ...
New Pharmaceutical Company to Target Alzheimer's Disease
... brains of Alzheimer's
disease sufferers. In addition, Archer Pharmaceuticals, Inc. has several
other agents in the preclinical stage, including Gamma secretase
and BACE Inhibitors. These approaches are designed to attack the
Alzheimer's disease soluble amyloid in different ways, providing
EnVivo Pharmaceuticals Announces Executive Appointment
...Schizophrenia, a Histone Deacetylase (HDAC) program for
Huntington's disease, EVP2442 program for neuron-protection and the PDE10
inhibitor and gamma- secretase
modulator programs. For more information see
Secretase in Biological Products